The latest issue of Medical Technology magazine is out now. Read it for free online on all devices.

Ongoing investigations in the US have revealed telemedicine’s vulnerability to fraudulent activity, with the recent Operation ‘Happy Clickers’ targeting fraud losses of more than $7m. We find out how fraudsters are gaming the US healthcare system under the guise of telemedicine and what can be done about it.

Last year, a court told the FDA it had wrongly classified a device as a drug, raising questions about how medicines and devices are defined by the agency. In this issue, we explore which products fall into the grey area between drugs and devices and the financial and regulatory consequences for companies whose products are moved from one category to another.

Also in this issue, we speak to XIL Health founder and CEO Susan Lang about the future potential of 3D printed drugs. We hear why Lang believes 3D printing in drug manufacturing could revolutionise personalised medicine, democratise access to medicines, improve sustainability in the supply chain and speed up the response time when infectious diseases spread.

Read the latest issue of Medical Technology  for all this as well as the latest news, comment and data from GlobalData.

You can also subscribe here to receive email notifications when a new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.